JNJ reports Q1 adjusted EPS $2.71 (+12.4% YoY); declares 4.2% dividend increase to $1.24/quarter

JOHNSON & JOHNSON

2024-Q1 EPS reported $1.34 revenue$21,383,000,000

Worldwide sales $21.38B, up 2.3% total (6.0% ex-COVID-19 vaccine); MedTech up 4.5%, Innovative Medicine ex-vaccine up 6.9%
GAAP net earnings from continuing ops $5.35B ($2.20 diluted EPS) vs $0.49B loss in prior year (large litigation charges skewed comparison)
Adjusted net earnings $6.58B, up 3.8%; adjusted diluted EPS $2.71 vs $2.41, +12.4%
Board raises quarterly dividend to $1.24/share (from $1.19), a 4.2% increase; marks 62nd consecutive annual increase
New indicated annual dividend $4.96/share; payable June 4, 2024 to holders of record May 21, 2024

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

JOHNSON & JOHNSON reported first quarter ended March 31, 2024 results: revenue $21,383 million, net income $5,354 million, EPS $2.20.

Period: first quarter ended March 31, 2024
Revenue: $21,383 million
Net income: $5,354 million
EPS: $2.20
Result: reported results

Exact text from the filing

On April 16, 2024, Johnson & Johnson issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the first quarter ended March 31, 2024.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

JOHNSON & JOHNSON filing history →

Source: SEC EDGAR

accession 0000200406-24-000031

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.